Tvardi Therapeutics (NASDAQ:TVRD) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Tvardi Therapeutics (NASDAQ:TVRD) from a strong sell rating to a sell rating in a research note released on Saturday.

A number of other research analysts have also recently issued reports on TVRD. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Wednesday, July 8th. HC Wainwright began coverage on shares of Tvardi Therapeutics in a report on Monday, June 8th. They set a “buy” rating and a $9.00 target price on the stock. BTIG Research cut their price target on Tvardi Therapeutics to $5.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Raymond James Financial raised shares of Tvardi Therapeutics from a “market perform” rating to an “outperform” rating and set a $10.00 price objective on the stock in a research report on Wednesday, July 8th. Finally, UBS Group upgraded Tvardi Therapeutics to an “outperform” rating and set a $10.00 target price on the stock in a report on Wednesday, July 8th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $18.00.

Tvardi Therapeutics Stock Performance

TVRD opened at $1.78 on Friday. The firm’s fifty day moving average is $2.38 and its two-hundred day moving average is $3.09. The firm has a market cap of $23.75 million, a PE ratio of -0.64 and a beta of 0.39. Tvardi Therapeutics has a twelve month low of $1.50 and a twelve month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.04). Equities analysts forecast that Tvardi Therapeutics will post -2.35 EPS for the current fiscal year.

Institutional Trading of Tvardi Therapeutics

Hedge funds have recently made changes to their positions in the business. GSA Capital Partners LLP acquired a new position in shares of Tvardi Therapeutics during the 2nd quarter worth approximately $34,000. Arax Advisory Partners lifted its holdings in Tvardi Therapeutics by 277.2% during the 4th quarter. Arax Advisory Partners now owns 8,400 shares of the company’s stock valued at $36,000 after purchasing an additional 6,173 shares during the last quarter. JPMorgan Chase & Co. acquired a new stake in Tvardi Therapeutics during the 2nd quarter valued at $39,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Tvardi Therapeutics during the second quarter worth $43,000. Finally, HRT Financial LP bought a new position in Tvardi Therapeutics during the fourth quarter worth $47,000. 44.66% of the stock is owned by institutional investors and hedge funds.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.